Each year, 20,000 new cases of primary brain tumor are diagnosed in the United States. Traditional treatment options include surgery, radiation therapy and chemotherapy. Though recent research has opened up new avenues of exciting treatment options for patients.
According to Dr. Karen Fink, M.D., a neurologist on the medical staff at Baylor University Medical Center at Dallas and a principal investigator with Baylor Research Institute, much of the new research in brain tumor treatment is focused on studying individual tumors at the molecular and genetic level.
This allows clinicians to pick a treatment regimen that has the best probability of success for each patient, rather than a “one size fits all” approach.
Dr. Fink, who recently presented a Focus on Research talk titled “To Chemo, or Not to Chemo” at Baylor, is participating in several clinical trials that offer innovative therapies for newly diagnosed or recurrent malignant brain tumors.
One trial involves the creation of a vaccine for the treatment of newly diagnosed brain tumors. For that trial, a sample of the patient’s tumor is taken during surgery and used to create a vaccine to trigger the body to fight the tumor.
Another treatment being studied involves a device that the patient can wear, which delivers electric fields directly to the scalp to interrupt and slow tumor growth.
Dr. Fink and Baylor University Medical Center at Dallas are proud to be a part of advancing brain tumor care in the Dallas-Fort Worth area.
This post was contributed by Michael P. Kogan, practice administrator, Neuro-Oncology Associates, a Baylor-Health Texas affiliate